Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference
Myriad Genetics (NASDAQ: MYGN) announced that its CEO, Paul J. Diaz, and Chief Scientific Officer, Dale Muzzey, will present at the 41st Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Myriad Genetics (NASDAQ: MYGN) announced that its CEO, Paul J. Diaz, and Chief Scientific Officer, Dale Muzzey, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 4:30 p.m. PST/7:30 p.m. EST. The presentation will be available via a live webcast on the company's Investor Relations website, with an archived version accessible later that day. Additionally, COO Nicole Lambert will join a panel discussion on global precision medicine at the Goodwin + KPMG Symposium on January 11, 2023, at 10:45 a.m. PST/1:45 p.m. EST.
Details
News Market Reaction – MYGN
The recorded move for MYGN in the trading session of this news was +4.91%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SALT LAKE CITY, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Paul J. Diaz, president and chief executive officer, and Dale Muzzey, chief scientific officer, will present at the 41st Annual J.P. Morgan (JPM) Healthcare Conference on Monday, Jan. 9, 2023 at 4:30 p.m. PST/7:30 p.m. EST.
The presentation will be available through a live webcast on the Myriad Genetics Investor Relations website. An archived edition of the presentation will be available later that day.
Also during the JPM Conference, Nicole Lambert, chief operating officer, will be participating in a panel discussion about global precision medicine at the Goodwin + KPMG 4th Annual Symposium on Wednesday, Jan. 11 at 10:45 a.m. PST/1:45 p.m. EST.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. Fast Company named Myriad among the World’s Most Innovative Companies for 2022. For more information, visit www.myriad.com.
Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, SneakPeek, Health.Illuminated., RiskScore, Prolaris, GeneSight, and EndoPredict are trademarks or registered trademarks of Myriad Genetics, Inc. © 2022 Myriad Genetics, Inc. All rights reserved.
| Media Contact: Megan Manzari (385) 318-3718 Megan.Manzari@myriad.com | Investor Contact: Matt Scalo (801) 584-3532 Matt.Scalo@myriad.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.